Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer.

Hunter KU, Fernandes LL, Vineberg KA, McShan D, Antonuk AE, Cornwall C, Feng M, Schipper MJ, Balter JM, Eisbruch A.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):676-82. doi: 10.1016/j.ijrobp.2013.07.040. Epub 2013 Sep 10.

2.

Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.

Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A.

Head Neck. 2014 Jan;36(1):120-5. doi: 10.1002/hed.23275. Epub 2013 Jun 1.

3.

Neck spasm after chemoradiotherapy for head and neck cancer: natural history and dosimetric correlates.

Hunter KU, Worden F, Bradford C, Prince M, McLean S, Wolf G, Chepeha DB, Eisbruch A.

Head Neck. 2014 Feb;36(2):176-80. doi: 10.1002/hed.23284. Epub 2013 Apr 4.

4.

Clinical review of physical activity and functional considerations in head and neck cancer patients.

Hunter KU, Jolly S.

Support Care Cancer. 2013 May;21(5):1475-9. doi: 10.1007/s00520-013-1736-4. Epub 2013 Feb 17. Review.

PMID:
23417564
5.

Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.

Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CS, Chepeha DB, Eisbruch A.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):935-40. doi: 10.1016/j.ijrobp.2012.08.030. Epub 2012 Oct 3.

6.

Pattern of failure after high-dose thoracic radiation for non-small cell lung cancer: the University of Michigan experience.

Hunter KU, Kong FM, Chetty IJ, Cronin P, Tatro D, Marn C, Hayman JA, Ten Haken RK.

J Radiat Oncol. 2012 Sep;1(3):267-272.

7.

Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.

Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):921-6. doi: 10.1016/j.ijrobp.2011.08.022. Epub 2011 Dec 28.

PMID:
22208966
8.

Advances in imaging: target delineation.

Hunter KU, Eisbruch A.

Cancer J. 2011 May-Jun;17(3):151-4. doi: 10.1097/PPO.0b013e31821d7e35. Review.

PMID:
21610467
9.

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.

Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK.

Neuro Oncol. 2008 Apr;10(2):208-15. doi: 10.1215/15228517-2007-059. Epub 2008 Mar 3.

Supplemental Content

Loading ...
Support Center